111 related articles for article (PubMed ID: 11078915)
1. Expression of fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma.
Fujieda S; Sunaga H; Tsuzuki H; Fan GK; Ito T; Sugimoto C; Saito H
Cancer Lett; 2000 Dec; 161(1):73-81. PubMed ID: 11078915
[TBL] [Abstract][Full Text] [Related]
2. Effects of FasL expression in oral squamous cell cancer.
Fang L; Sun L; Hu FF; Chen QE
Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
[TBL] [Abstract][Full Text] [Related]
3. Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma.
Das SN; Khare P; Singh MK; Sharma SC
Indian J Med Res; 2011 Jul; 134(1):54-60. PubMed ID: 21808135
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma.
Loro LL; Vintermyr OK; Johannessen AC; Liavaag PG; Jonsson R
J Oral Pathol Med; 1999 Feb; 28(2):82-7. PubMed ID: 9950255
[TBL] [Abstract][Full Text] [Related]
5. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
Chien MH; Chang WM; Lee WJ; Chang YC; Lai TC; Chan DV; Sharma R; Lin YF; Hsiao M
Mol Cancer Ther; 2017 Jun; 16(6):1102-1113. PubMed ID: 28292939
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL
Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166
[TBL] [Abstract][Full Text] [Related]
7. Expression of Fas and Fas-ligand and analysis of argyrophilic nucleolar organizer regions in squamous cell carcinoma: relationships with tumor stage and grade, and apoptosis.
Guler N; Uckan S; Celik I; Oznurlu Y; Uckan D
Int J Oral Maxillofac Surg; 2005 Dec; 34(8):900-6. PubMed ID: 15907374
[TBL] [Abstract][Full Text] [Related]
8. Reliability of platelet-derived endothelial cell growth factor as a prognostic factor for oral and oropharyngeal carcinomas.
Tsuzuki H; Sunaga H; Ito T; Narita N; Sugimoto C; Fujieda S
Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1071-8. PubMed ID: 16365220
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis.
Chen Q; Samaranayake LP; Zhen X; Luo G; Nie M; Li B
Oral Oncol; 1999 Nov; 35(6):548-53. PubMed ID: 10705088
[TBL] [Abstract][Full Text] [Related]
11. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
12. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
13. Expression of Fas/FasL in patients with oral lichen planus.
Hadzi-Mihailovic M; Raybaud H; Monteil R; Jankovic L
J BUON; 2009; 14(3):487-93. PubMed ID: 19810143
[TBL] [Abstract][Full Text] [Related]
14. Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
Zepeda-Nuño JS; Guerrero-Velázquez C; Del Toro-Arreola S; Vega-Magaña N; Ángeles-Sánchez J; Haramati J; Pereira-Suárez AL; Bueno-Topete MR
Pathol Oncol Res; 2017 Apr; 23(2):345-353. PubMed ID: 27628319
[TBL] [Abstract][Full Text] [Related]
15. [Expression and significance of Fas and FasL protein in squamous cell carcinoma of larynx].
Shi L; Li G; Zhu C
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Dec; 16(12):661-2. PubMed ID: 12669436
[TBL] [Abstract][Full Text] [Related]
16. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
Satchell AC; Barnetson RS; Halliday GM
Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
[TBL] [Abstract][Full Text] [Related]
17. [The expression of Fas, FasL and Bcl-2 on RMA cells during the process of apoptosis induced by chemotherapeutic drugs].
Zhu HL; Wang YZ; Yu L; Li B; Yao SQ; Lou FD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Feb; 10(1):35-9. PubMed ID: 12513834
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma.
Ito T; Fujieda S; Tsuzuki H; Sunaga H; Fan G; Sugimoto C; Fukuda M; Saito H
Cancer Lett; 1999 Jun; 140(1-2):81-91. PubMed ID: 10403545
[TBL] [Abstract][Full Text] [Related]
19. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
20. Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.
Frassanito MA; Silvestris F; Silvestris N; Cafforio P; Camarda G; Iodice G; Dammacco F
Clin Exp Immunol; 1998 Nov; 114(2):179-88. PubMed ID: 9822274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
